First-Quarter 2019 Summary (comparisons to prior-year period)
Net sales of $443.5 million grew 7%, organic sales growth was 11%
Reported-diluted EPS of $0.73 increased 26%
Adjusted-diluted EPS of $0.74 increased 19%
Repurchased 800,000 shares of common stock for $83.1 million
Company reaffirms full-year 2019 net sales guidance and raises full-year 2019 adjusted-diluted EPS guidance to a new range between $2.80 and $2.90, compared to a prior range between $2.77 and $2.89.
"Adjusted-diluted EPS" and "organic sales growth" are Non-U.S. GAAP measurements. See discussion under the heading "Non-U.S. GAAP Financial Measures" in this release.
"Our organization executed on multiple fronts to deliver a strong start to the year, with good growth performance across all segments and market units," said Eric M. Green, President and Chief Executive Officer. "With double-digit organic sales growth in high-value products, coupled with continued execution on Global Operations strategic [REMOVIDO]s, we expanded adjusted operating profit margin by 250 basis points."
West Announces First-Quarter 2019 Results | West Pharmaceutical Services, Inc.
